Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Neurological Injury

DMT for Neurological Injury

2 papers and 0 clinical trials exploring dmt as a treatment for neurological injury.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 15 million individuals experience a stroke annually, while traumatic brain injuries occur in around 69 million people worldwide each year.

Neurological Injury

Neurological injury encompasses various forms of brain damage resulting from trauma, strokes, or other factors, leading to significant functional impairment. Recent research into psychedelic compounds presents promising avenues for innovative therapeutic interventions aimed at enhancing recovery and alleviating associated psychological conditions such as PTSD and depression.

Full Neurological Injury profile

Academic Research

2 papers
Open Accessindividual

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomized, double‑blind, placebo‑controlled study found that a 30‑s bolus followed by a 6‑hour intravenous DMT infusion (maximal exposures ≈35 ng/mL) was well tolerated in healthy volunteers with no serious adverse events and only mild, rapidly occurring psychedelic effects. Moderate interindividual pharmacokinetic variability was observed and the highest dose produced transient reductions in sustained attention, postural stability and occipital alpha power, providing a safety and PK/PD basis for future proof‑of‑mechanism studies in patient populations.

Published
May 13, 2025
Journal
Clinical and Translational Science
Authors
Zuiker, R. G. J. A., Otto, M. E., Bryan, C. S., Stewart, N., Stillwell, C., de Kam, M. L., van Leuken, M. B., van Gerven, J. M. A., Jacobs, G. E., van der Heijden, K. V.
Open Accessindividual

The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells

This in vitro study investigated whether DMT acts neuroprotective against oxidative stress within cultured neurons and immune cells derived from human precursor cells. Results indicate that DMT robustly increases the survival of these cells in response to severe oxygen deprivation, through activation of the Sig-1 receptor, a key modulator of cellular oxidative stress. The authors postulate that DMT may be endogenously generated to mitigate oxidative stress occasioned by adverse brain injuries such as ischemic infarcts.

Published
September 14, 2016
Journal
Frontiers in Neuroscience
Authors
Ahmad, M., Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., Frecska, E.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Neurological Injury yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Neurological Injury trials Full DMT profile Full Neurological Injury profile